Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
about
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contraTargeting molecular resistance in castration-resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesAbiraterone in the treatment of metastatic castration-resistant prostate cancerCurrent clinical challenges in prostate cancerTargeting the androgen receptor with steroid conjugatesChemotherapy and its evolving role in the management of advanced prostate cancerQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesSequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapyTargeting the adaptive molecular landscape of castration-resistant prostate cancerAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Androgen receptor splice variants determine taxane sensitivity in prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityAndrogen receptor as a driver of therapeutic resistance in advanced prostate cancer.The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.Practical guide to the use of abiraterone in castration resistant prostate cancer.SEOM clinical guidelines for the treatment of metastatic prostate cancerPhase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patientsManagement of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agentsAndrogen pathway resistance in prostate cancer and therapeutic implicationsAssessing the utility of cabazitaxel in mCRPCVery Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall SurvivalIncreased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancerPartial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report.The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.Metabolic and toxicological considerations of newly approved prostate cancer drugs.Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?
P2860
Q24289204-6EB27148-81BA-4F0A-A5DD-020C607C2DE5Q26795445-ADC31FC8-9E2B-4C8E-9A59-31A9B60FA696Q26796568-550FDEFE-0882-4634-8D30-1DEB517E3213Q26796704-B9B94048-AE0F-47B0-A372-D5921D7FC889Q26853635-F32419A2-9B17-4F7A-B4B1-517E32B5896CQ26866036-3B49CDC6-DE16-4CDB-9A61-3396FDE7E396Q26995692-AF4920DA-6CE3-410E-868F-B2E6A4A8244BQ27008883-A5A36DC2-630E-47C4-83DF-AC1004B2E9F4Q27011642-16A4DC8E-40C2-47C3-9E42-FC551330E26AQ27022715-BE6B5665-F22B-422F-BC6A-C67100DF269EQ27022821-90E6A184-55CE-43C1-BE2B-75EE84F566F8Q30244818-322D9D93-0CAE-4E6C-9E6F-CA06C54CCE4BQ30248275-6642A3BF-B077-4CF3-8972-187A6A9EEF2DQ30577613-7F750998-0432-4004-BE1F-1DEE6BFF821EQ33621403-1C230CBC-6260-4990-988F-70CDBA08BFC4Q33656820-415D8BD2-42A2-4869-B165-225F50E9B951Q33775723-2044193D-67E2-4265-841F-AFA2CBA70539Q33946666-DFA576A3-7545-429A-A02D-0B19DC9BB74FQ34070638-CE5B98CE-CE15-4349-B62A-0C0809DF5F64Q34553405-A1740BB4-9D9F-4075-8541-372E6DAE76B8Q35328550-C92B885D-CBBB-42EA-92B5-6D43C6F86B6BQ35358010-E1D3FACC-C2A6-4342-9AC7-00AA4C87E67DQ35602593-6CF714D9-0C7C-4A33-AF30-D85E34862A79Q35879087-A6469B82-FEC8-4FF4-8101-AC280A119751Q35932706-43DD253D-47CF-4E51-800C-42F7E8787D18Q36243639-F55EDA60-C549-4760-915C-CFBBCC9EA0DDQ36410270-A788F0C1-048D-4C86-A5E3-9DFF16E9FB2DQ36414184-25E5A630-1092-4AFB-A2AE-D9E314D1743DQ36416370-5D417C2F-AE68-459E-B13A-AC8567FEC410Q36823066-085B9CCE-B6A1-49B7-AC30-A03808587C52Q36909750-F1D508E0-E013-45A2-A11D-AD7BDCF2FC74Q36910062-CBE48F80-51C2-457C-BA66-78CEDFC81D12Q36981441-380402D3-83FD-4DCB-B143-0618C47C1CEEQ37227713-B30B73CA-72C7-4860-8C6A-90A6556EB25AQ37735587-028F2115-520B-4410-9AD7-4B822AF2C764Q38097373-416F6928-4748-4ACB-B5C3-B44F85C31BDCQ38098596-BECE386F-1F6F-4392-9DDB-A3F93EA2B522Q38181005-18970245-B217-434C-8509-05840D25344AQ38183819-E8AEEBDE-B115-4F53-9422-0B17D9F5CC8EQ38195921-6B7CFC66-5A69-472E-9175-28A82032BBAE
P2860
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antitumour activity of docetax ...... evidence for cross-resistance?
@en
Antitumour activity of docetax ...... evidence for cross-resistance?
@nl
type
label
Antitumour activity of docetax ...... evidence for cross-resistance?
@en
Antitumour activity of docetax ...... evidence for cross-resistance?
@nl
prefLabel
Antitumour activity of docetax ...... evidence for cross-resistance?
@en
Antitumour activity of docetax ...... evidence for cross-resistance?
@nl
P2093
P356
P1433
P1476
Antitumour activity of docetax ...... evidence for cross-resistance?
@en
P2093
A H M Reid
A Mulick Cassidy
A Sarvadikar
D Bianchini
E Sheridan
E Thompson
P304
P356
10.1093/ANNONC/MDS119
P577
2012-07-05T00:00:00Z